Cargando…

[(68)Ga]-Pentixafor PET/CT for CXCR4-Mediated Imaging of Vestibular Schwannomas

We have recently demonstrated CXCR4 overexpression in vestibular schwannomas (VS). This study investigated the feasibility of CXCR4-directed positron emission tomography/computed tomography (PET/CT) imaging of VS using the radiolabeled chemokine ligand [(68)Ga]Pentixafor. Methods: 4 patients with 6...

Descripción completa

Detalles Bibliográficos
Autores principales: Breun, Maria, Monoranu, Camelia M., Kessler, Almuth F., Matthies, Cordula, Löhr, Mario, Hagemann, Carsten, Schirbel, Andreas, Rowe, Steven P., Pomper, Martin G., Buck, Andreas K., Wester, Hans-Jürgen, Ernestus, Ralf-Ingo, Lapa, Constantin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6581743/
https://www.ncbi.nlm.nih.gov/pubmed/31245296
http://dx.doi.org/10.3389/fonc.2019.00503
Descripción
Sumario:We have recently demonstrated CXCR4 overexpression in vestibular schwannomas (VS). This study investigated the feasibility of CXCR4-directed positron emission tomography/computed tomography (PET/CT) imaging of VS using the radiolabeled chemokine ligand [(68)Ga]Pentixafor. Methods: 4 patients with 6 primarily diagnosed or pre-treated/observed VS were enrolled. All subjects underwent [(68)Ga]Pentixafor PET/CT prior to surgical resection. Images were analyzed visually and semi-quantitatively for CXCR4 expression including calculation of tumor-to-background ratios (TBR). Immunohistochemistry served as standard of reference in three patients. Results: [(68)Ga]Pentixafor PET/CT was visually positive in all cases. SUV(mean) and SUV(max) were 3.0 ± 0.3 and 3.8 ± 0.4 and TBR(mean) and TBR(max) were 4.0 ± 1.4 and 5.0 ± 1.7, respectively. Histological analysis confirmed CXCR4 expression in tumors. Conclusion: Non-invasive imaging of CXCR4 expression using [(68)Ga]Pentixafor PET/CT of VS is feasible and could prove useful for in vivo assessment of CXCR4 expression.